The UCSF-GIVI CFAR Immunology Core is dedicated to stimulating translational research that explores and defines the immunological abnormalities present in HIV infection and that promotes improvements in the care of HIV-infected patients at both domestic and international sites. To accomplish this goal, the Core offers a wide array of immunological services including multiparameter flow cytometric assays of immune cell phenotype and immune function (proliferation, cytotoxicity, cytokine production and cell signaling);specialized tissue processing of bone marrow, lymph node and gut associated lymphoid tissues plus isolation of specific subsets of lymphocytes by immunomagnetic bead or FACS sorting and analysis of downstream signaling pathways within these purified cell subsets. Overall, the Core provides four complementary lines of service including: 1) customized immune assays designed to meet individual investigator needs;2) access to state-of-the-art flow cytometry including infected and uninfected cell sorting and cell analysis;3) development and optimization of new immunological assays, technologies and related services and 4) training, mentoring and education of early-career investigators, senior investigators from other disciplines, and laboratory staff. The Core provides services from two different campus sites including the Core Immunology Laboratory located within the Division of Experimental Medicine at the San Francisco General Hospital and the Gladstone Flow Core located at Mission Bay. During the last funding period, the Immunology Core supported 80 different studies from 65 different investigators, introduced 28 new immune assays, developed sixty-five 6-12 color flow cytometry panels, contributed to 59 peer-reviewed publications, trained 45 young investigators and helped leverage more than 15 million dollars in new grant support. A new top priority for the Immunology Core involves enhancing immunological expertise and capacity in Tororo, Uganda and providing mentoring and training in translational immunology to investigators at this site. The core will also continue to evaluate and introduce new technologies to accelerate the research progress of CFAR investigators including the use of intracellular branched DNA technology for detection of latent HIV infection and the use of microparticles to stage cardiovascular disease during HIV infection.

Public Health Relevance

The Immunology Core provides state-of-the art immunology assay service and instrumentation in support of basic, translational and multidisciplinary research projects that investigate the complex interactions between HIV, the immune response to HIV, and novel therapeutic interventions aimed at modifying the immune response or eradicating latent infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027763-21
Application #
8295384
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
21
Fiscal Year
2012
Total Cost
$313,985
Indirect Cost
$80,009
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Scherzer, Rebecca; Shah, Sanjiv J; Secemsky, Eric et al. (2018) Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. Circ Heart Fail 11:e004312
Shehata, Hesham M; Khan, Shahzada; Chen, Elise et al. (2018) Lack of Sprouty 1 and 2 enhances survival of effector CD8+ T cells and yields more protective memory cells. Proc Natl Acad Sci U S A 115:E8939-E8947
Tang, Eric C; Vittinghoff, Eric; Anderson, Peter L et al. (2018) Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr 77:193-198
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Yoon, Christina; Semitala, Fred C; Asege, Lucy et al. (2018) Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. Am J Respir Crit Care Med :
Tang, Weiming; Liu, Chuncheng; Cao, Bolin et al. (2018) Receiving HIV Serostatus Disclosure from Partners Before Sex: Results from an Online Survey of Chinese Men Who Have Sex with Men. AIDS Behav 22:3826-3835
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Tamraz, Bani; Huang, Yong; French, Audrey L et al. (2018) A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clin Pharmacol Ther 104:949-956
Clutton, Genevieve Tyndale; Jones, R Brad (2018) Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol 9:1452

Showing the most recent 10 out of 1541 publications